MEDIA RELEASE

VivaZome and collaborators at The University of Queensland and Australian National University to present at ISEV international exosome conference

17 May 2023 - Melbourne, Australia: VivaZome Therapeutics Pty Ltd ("VivaZome") is pleased to announce that two posters with new data highlighting the functional potential of extracellular vesicles ("EVs") will be presented at the upcoming annual meeting of the International Society of Extracellular Vesicles ("ISEV") to be held this week on 17-21 May 2023 in Seattle, USA.

The poster, **"Local administration of extracellular vesicles from bone marrow-derived mesenchymal stem cells restores homeostatic communication pathways and slows the progression of retinal degeneration"** (Wooff *et al*) is co-authored by scientists from Australian National University (ANU) and VivaZome. The authors conclude that "BM-MSC-EV are a potential therapeutic EV source to slow the progression of retinal degeneration, and can potentially be used to deliver current and future therapeutics".

The second poster, "**Bioengineering exosomes to enhance brain targeting in a mouse traumatic brain injury model**" (Chen e*t al*), co-authored by scientists from The University of Queensland (UQ) and VivaZome, concludes that "The expression of Lamp2b-RVG increases the uptake of exosomes by neuroblastoma cells and the accumulation of exosomes in the brain after systemic administration".

Dr David Haylock, CEO of VivaZome, in attendance at ISEV, said: "We are delighted to be working with world-leading scientists at ANU and UQ as we jointly strive to develop new customised EV-based approaches to treat retinal disease and brain injury. These compelling new data highlight our strong progress"

Ms Xenia Sango, Chief Operating Officer at VivaZome is also in attendance at ISEV and will continue her contribution as a member of ISEV International Task Force on Regulatory Affairs and Clinical Use of EV-based Therapeutics. The Task Force's major goal is the application of relevant regulatory guidance for EVs as investigational new drugs (INDs) in clinical studies, as well as to support safe and effective EV-based treatment concepts worldwide.

The ISEV Annual Meeting is the major scientific conference in the field of EVs. It brings together researchers and scientists from around the world with over 1,200 attendees annually. The conference will cover all aspects of EV research from basic to clinical, and both diagnostic and therapeutic applications.

For further information, contact:

Dr David Haylock, CEO, VivaZome Therapeutics Pty Ltd
David.haylock@vivazome.com
Phone: +61 (0) 439 617 657

About VivaZome:
VivaZome Therapeutics Pty Ltd is a privately-held Australian biotech company, with operational headquarters at the La Trobe University in Melbourne, Australia. VivaZome aims to develop and commercialise customised exosome-based therapies for debilitating and/or life-threatening disorders, with a focus on neurological disorders, retinal disease and ischaemic conditions. VivaZome is developing new technologies, intellectual property and manufacturing processes that are applicable generically to exosome therapies. These will underpin the Company's development of specific exosome products for its target indications. The VivaZome team has extensive expertise in the development and commercialisation of biological therapies, together with a wide network of expert contacts in the Australian and global biotech communities.

VivaZome acknowledges the support of the Department of Industry and Science through the CRC-P program, and the contribution of its CRC-P partners: Australian National University, the University of Queensland, La Trobe University, Cytiva and SeerPharma Pty Ltd.

For more information, please visit www.vivazome.com